Form 4 for EW Edwards Lifesciences
Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-12 · accession 0001225208-26-001986 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-17 | 2026-02-16+ | EW | Lippis Daniel J. | CVP, TAVR | F - Tax | $75.87 | -456 | 34.6K | -1% | -$34.6K |
| 2026-02-17 | 2026-02-12 | EW | Lippis Daniel J. | CVP, TAVR | A - Grant | $0.00 | +12.8K | 34.8K | +58% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | F | D | 198 | $75.87 | 34,365.91 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-12 | A | A | 12,820 | $0.00 | 34,821.91 | D | — | — | (F1) These restricted stock units were granted on February 12, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
| 3 | Common | Common Stock | 2026-02-16 | F | D | 258 | $75.87 | 34,563.91 | D | — | — |